HOME
ABOUT US
ADVERTISE
SUBSCRIBE
SITE MAP
HELP
CONTACT
WORK FOR US
Friday
10 September 2010
Make BTN my HomePage
PIPELINE PROGRESS STORIES
[ 1042 Results - Showing Results 1 to 30 ]
Novogen offers treats to Marshall
(Thursday, 9 September 2010)
SYDNEY-based biotechnology company Novogen has agreed to sell its isoflavone-related intellectual property portfolio to US subsidiary and licensee Marshall Edwards in exchange for stock.
Full Story...
Pipeline Progress: QRxPharma, Tyrian, Prana and more
(Monday, 6 September 2010)
AS Pharmaxis’s recent “failed” clinical trial can attest, comparing results from two dosings of the same therapeutic carries the risk that an effective treatment can still miss endpoints.
Full Story...
Immuron delivers tasty NASH
(Tuesday, 24 August 2010)
FOLLOWING a successful Phase 1/2 trial of its dairy-derived colostrum powder in patients with metabolic condition fatty liver disease, immunotherapy product developer Immuron must choose whether to tackle insulin resistance, high blood fats or both as it advances its platform to US Food and Drug Administration-compliant trials.
Full Story...
Virax falls on HIV result
(Tuesday, 17 August 2010)
VIRAX has lost some 60% of its market capitalisation after investors punished it for the poor result from its HIV vaccine trial, which failed to elicit an immune response and missed primary and secondary endpoints.
Full Story...
University seeks partners
(Monday, 16 August 2010)
CURTIN University of Technology has showcased a number of innovative biotechnology projects which it is looking to partner or out-licence – including a technology to speed up pap smears and a potential alternative to malaria standard-of-care.
Full Story...
QRxPharma puts best hip forward
(Tuesday, 10 August 2010)
COMBINATION opioid developer QRxPharma has reported positive results from a 40-patient proof-of-concept study conducted in Germany, which showed better pain relief from an intravenous MoxDuo morphine-oxycodone combination than morphine alone for patients who are experiencing moderate to severe pain after hip-replacement surgery.
Full Story...
LCT plans pivotal study
(Thursday, 5 August 2010)
DIABETES treatment developer Living Cell Technologies has spoken of its plans for a two-year pivotal study after receiving approval from New Zealand’s health minister to extend a small dose-ranging trial of its Diabecell implant to additional, insulin-dependent diabetes patients.
Full Story...
Actinogen makes discovery
(Tuesday, 3 August 2010)
PERTH-based company Actinogen says it has discovered a new method to produce anacardic acid, a product that retails for close to $1000 a gram from fine chemical suppliers.
Full Story...
Novogen gets NASDAQ notice
(Tuesday, 27 July 2010)
AS Novogen prepares to “actively monitor” its share price, chairman Phillip Johnston has predicted a pipeline review at the pharmaceutical developer will be completed within six months.
Full Story...
Asthmatic cold-sufferers take Biota
(Tuesday, 27 July 2010)
DRUG developer Biota has started a 400-patient, multi-site clinical trial of US-based asthmatics with human rhinovirus, which it expects will cost up to $25 million and will be funded by cash-at-hand.
Full Story...
Prima beefs up board, enrols patients
(Tuesday, 27 July 2010)
THREE weeks after Prima BioMed’s chief executive retired from its board, the ovarian cancer treatments developer has appointed an interim chairman and reappointed Martin Rogers as managing director after receiving more than 200 complaints.
Full Story...
Mesoblast gets TGA green light
(Thursday, 22 July 2010)
BIOLOGIC products developer Mesoblast expects to see first commercial sales of its proprietary mesenchymal precursor cells in Australia by the end of the year after receiving a Therapeutic Goods Administration licence to manufacture and supply the adult stem cells.
Full Story...
Bio Briefs: KarmelSonix, Prana and BPH
(Tuesday, 20 July 2010)
THE United States Food and Drug Administration has granted KarmelSonix 510k market clearance for its wheeze and cough measurement device WHolter.
Full Story...
FDA lifts ChemGenex
(Thursday, 15 July 2010)
LATE-stage drug developer ChemGenex has recovered some lost ground, gaining up to 37% after the United States Food and Drug Administration invited it to file a new drug application for its chronic myeloid leukaemia treatment in patients who have failed therapy two or more times.
Full Story...
BioDiem pauses after Merck belt-tightening
(Tuesday, 13 July 2010)
WITH good news comes bad, it seems. BioDiem shares gained last Friday after an Indian product approval and then rested yesterday as the market absorbed uncertainty created by a Merck facility closure.
Full Story...
Pipeline Progress: Tissue Therapies, LCT and Antisense
(Tuesday, 13 July 2010)
BIOMEDICAL company Tissue Therapies has released further positive results from the Australian trials of its VitroGro wound-healing product in humans.
Full Story...
Clinuvel achieves results for shadow jumpers
(Tuesday, 13 July 2010)
LIGHT protectant drug developer Clinuvel has reported positive results from a 12-month Phase 3 study of its afamelanotide product Scenesse in patients with orphan indication erythropoietic protoporphyria, reporting reduced pain and more days spent in sunlight.
Full Story...
Virax readies for 2a result
(Thursday, 8 July 2010)
THERAPEUTIC vaccine developer Virax is preparing to announce results from a Phase 2a trial of its lead product, the HIV immunotherapy vaccine VIR201, conducted in South Africa.
Full Story...
Avexa shareholders roll board members
(Tuesday, 6 July 2010)
SHAREHOLDERS of Avexa have voted out chairman Nathan Drona and newly elected director Uri Ratner to replace them with experienced Australia-based biotechnology professionals Bruce Hewett and Steven Crowley, leaving only one serving board member in place.
Full Story...
Alimera lodges NDA, pSivida gains
(Thursday, 1 July 2010)
PSIVIDA has gained 10% on the NASDAQ after licensee Alimera Sciences submitted a new drug application to the US Food and Drug Administration for Iluvien in diabetic macular edema patients.
Full Story...
Phosphagenics extends Phase 2/3 start date
(Thursday, 1 July 2010)
TRANSDERMAL delivery specialist Phosphagenics has opened recruitment to a Phase 1b/2 clinical trial of its oxycodone combination patch to evaluate the best candidate for Phase 2/3 research program now set to begin by March 2011.
Full Story...
Biotron progresses hep c research
(Thursday, 1 July 2010)
HEPATITIS C drug developer Biotron says ethics approval has been received in Argentina for a two-nation Phase 2a combination trial of BIT225 with standard of care treatments with ACLIRES.
Full Story...
Strong wind rattles Pharmaxis
(Thursday, 24 June 2010)
THERAPEUTICS developer Pharmaxis’s share price has slid down by 33-47% after the company’s second Phase 3 trial in cystic fibrosis patients “narrowly missed” its primary endpoint – a result chief operating officer Gary Phillips has predicted is unlikely to be a “dealbreaker” with the US Food and Drug Administration.
Full Story...
HealthLinx OvPlex 2G study underway
(Tuesday, 15 June 2010)
HEALTHLINX has gained 14.3% in morning trade after Victorian Innovation Minister Gavin Jennings launched a new, international 1150-patient study of HealthLinx’s second-generation OvPlex test for ovarian cancer.
Full Story...
Bio Briefs: ARCs, CogState, BioProspect and more
(Tuesday, 15 June 2010)
THE Australian Research Collaboration Service has launched a new Compute Cloud service for researchers at publicly funded institutions which allows for large-scale data crunching with high-performance computers.
Full Story...
Eastland investment runs into trouble?
(Monday, 14 June 2010)
MALARIA treatment developer Eastland Medical Systems says its latest Phase 3 program is on schedule, while investee Berlin Pharma has apparently begun insolvency proceedings in Germany.
Full Story...
Avita shares spike over first US ReCell treatment
(Thursday, 10 June 2010)
AVITA Medical shares gained 22.7% this morning on positive results from the company’s first United States-based treatment of a patient with ReCell Spray-On Skin.
Full Story...
Bionomics achieves on-target VDA first
(Tuesday, 8 June 2010)
DRUG developer Bionomics has released positive safety data from a Phase 1 study of its lead cancer compound. Speaking to
BTN
from the US, chief executive and managing director Dr Deborah Rathjen called the trial important and said it was the first time a vascular disruptive agent had shown on-target activity that correlated with reduction of that target in patients.
Full Story...
Bio Briefs: ChemGenex, Burnet
(Monday, 7 June 2010)
CHEMGENEX has released positive safety data from a clinical trial of its lead product candidate in chronic myeloid leukaemia patients, as heavyweight Novartis released 18-month data showing its second-generation treatment for CML beat its first-gen product Gleevec.
Full Story...
Novogen swallows, falls 53%
(Thursday, 3 June 2010)
NOVOGEN must make some quick decisions on its pipeline after analysis of results from a Phase 3 study showed its oral phenoxodiol treatment in ovarian cancer patients did not halt disease progression or improve survival.
Full Story...
Prev
Next
Company Search
Story Search
Advanced Search
UPCOMING
EVENTS
ABIC 2010 - Bridging Biology and Business
14th International Biotechnology Symposium & Exhibition 2010
BIO India Partnering Conference 2010
OZBIO2010
2010 Livestock Biotech Summit
BioPartnering Europe
View all events
LATEST NEWS
Novogen offers treats to Marshall
Research frameworks must change
Agenix shines like $5M diamonds
Phylogica warns of $106M uncertainty
Bio People: ARTrinsic, iNova
UBI seeks CEO
BioDiem orphaned by FDA
BioDiem fights bird flu with CDC-Merck
Broadvector prepares $24.5M bang
Bio People: Australia, Research Australia, KarmelSonix and more *UPDATED*
Disclaimer
|
© Copyright Aspermont Ltd
|
Privacy Policy
|
Terms and Conditions
